Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 10/20 | 0.50 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540400 | 0.84 | MAPK1 (0.42) | TRPA1HSPB1EPAS1ALDH1A1HTT | |
| SCHEMBL5541162 | 0.84 | HTR1A (0.46) | HSPB1ALDH1A1L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL10456772 | 0.83 | TRPA1 (0.56) | TRPA1HSPB1EPAS1ALDH1A1 | |
| SCHEMBL2093908 | 0.81 | HSPB1 (0.38) | TRPA1HSPB1ALDH1A1L3MBTL1SLC6A2 | |
| SCHEMBL7634253 | 0.78 | CA1 (0.38) | ALDH1A1HTTL3MBTL1 | |
| SCHEMBL25187432 | 0.77 | EPAS1 (0.55) | TRPA1HSPB1EPAS1ALDH1A1HTT | |
| SCHEMBL1338646 | 0.77 | KDM4E (0.55) | TRPA1HSPB1ALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL30159449 | 0.77 | TRPA1 (0.53) | TRPA1HSPB1EPAS1ALDH1A1HTT | |
| SCHEMBL5536030 | 0.74 | CYP1A2 (0.40) | EPAS1ALDH1A1HTTL3MBTL1SLC6A2 | |
| SCHEMBL8124736 | 0.74 | TRPA1 (0.63) | TRPA1HSPB1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TRPA1 3038/4885HSPB1 1523/4885EPAS1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.